Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 and Ibrutinib in CLL
NCT03400176Phase 1Terminated
- Sponsor
- Novartis
- Start
- Apr 2018
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ianalumab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events up to 8.8 months and 4 more. Started Apr 2018; status: terminated.
02
Drugs
ianalumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03400176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400176.